Personalized Approaches to Cardiovascular Disease: Insights into FDA-Approved Interventions and Clinical Pharmacogenetics

Author:

Raoufinia Ramin12ORCID,Rahimi Hamid Reza2,Abbaszadeh Mahla3,Gholoobi Aida24,Saburi Ehsan2,Fakoor Farhad5,Alshakarchi Hawraa Ibrahim6,Gataa Ibrahim Saeed7,Hassanian Seyed Mahdi2,Ferns Gordon A.8,Khazaei Majid4,Avan Amir249ORCID

Affiliation:

1. Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran

2. Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3. Department of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran

4. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

5. Department University of of Paramedical Sciences, Iran University of Medical Sciences, Tehran, Iran

6. Al-Zahraa Center for Medical and Pharmaceutical Research Sciences (ZCMRS), Al-Zahraa University for Women, Kerbala 56001, Iraq

7. College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq

8. Division of Medical Education, Brighton & Sussex Medical School, Falmer, Brighton, Sussex BN1 9PH, UK

9. Faculty of Health, School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane 4059, Australia

Abstract

Abstract: Cardiovascular diseases place a considerable burden on global health systems, contributing to high rates of morbidity and mortality. Current approaches to detecting and treating Cardiovascular Diseases (CVD) often focus on symptomatic management and are initiated after the disease has progressed. Personalized medicine, which tailors medical interventions to individual characteristics, has emerged as a promising strategy for improving cardiovascular health outcomes. This article provides an overview of personalized medicine in the context of CVD, with a specific emphasis on FDA-approved interventions. It explores the potential benefits, challenges, and future directions of personalized medicine in cardiovascular disorders. By reviewing the advancements in this field, this article underscores the importance of early detection, intervention, and innovative treatment options in reducing the impact of CVD on individuals and society.

Publisher

Bentham Science Publishers Ltd.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3